ArticleJAMA oncology2020
Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma.
Article in JAMA oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.JCO oncology practice · 2026Observational
- Comparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study.Journal of cancer policy · 2025Article
- High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare.JAMA health forum · 2025Article
- Increases in Medicare Spending and Use after Private Equity Acquisition of Retina Practices.Ophthalmology · 2024Article
- Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.Journal of general internal medicine · 2022Article
- Prescribing of low- versus high-cost Part B drugs in Medicare Advantage and traditional Medicare.Health services research · 2022Article
- Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.Journal of the National Cancer Institute · 2022Article
- Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms.JCO oncology practice · 2022Review
- Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma.Cancers · 2021Review
- Payment incentives and the use of higher-cost drugs: a retrospective cohort analysis of intravenous iron in the Medicare population.The American journal of managed care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.